Back to Newsroom

StemCells, Inc. Announces Webcast to Discuss Interim Results From the First Cohort in Its Phase II Study in Cervical Spinal Cord Injury

StemCells, Inc.(NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, will host a webcast to discuss the six-month interim results from the first cohort in its Phase II PathwayTM Study in cervical spinal cord injury. The Company will also provide a progress update on the second 40-patient cohort which is currently enrolling patients.

Read more here.